Answers are grounded in this paper and cite their sources.
Retrospective cohort study compares abatacept and TNFi initiation impacts on treatment in rheumatoid arthritis patients, suggesting implications for selection factors.
Aim: To compare characteristics of patients with anticitrullinated protein antibody-positive (ACPA+) and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated abatacept or a tumor necrosis factor inhibitor (TNFi) as a first-line biologic disease-modifying antirheumatic drug (bDMARD), and to identify factors associated with first-line bDMARD selection. Materials & methods: This retrospective cohort study abstracted data for patients with ACPA+/RF+ RA initiating abatacept or a TNFi as a first-line bDMARD between 1 January 2015 and 19 February 2020. Patient characteristics were compared using chi-square/Fisher exact tests (categorical variables) and Wilcoxon tests (continuous variables). Adjusted odds ratios (OR; 95% confidence interval [CI]) of initiating abatacept versus TNFi were estimated using 2-level logistic regression. Results: The analysis cohort included 301 patients who initiated abatacept and 203 patients who initiated a TNFi. Time from RA diagnosis to first-line initiation (>2 years vs <1 year; OR [95% CI] 2.9 [1.4-6.1]), high and moderate disease activity (versus low; 5.0 [1.8-13.9] and 4.2 [1.5-11.6], respectively), and conventional synthetic (cs) DMARD use within 12 months prior to initiation (versus no csDMARD use; 2.0 [1.1-3.6]) were associated with higher odds of initiating abatacept versus a TNFi (all p < 0.05). Patients with Medicare/other insurance had increased odds of initiating abatacept (versus TNFi) as age increased. Baseline ACPA >250 AU/ml was associated with lower odds of initiating abatacept over a TNFi (versus ACPA 20-250 AU/ml; 0.4 [0.2-0.8]; p < 0.01). Conclusion: In this real-world study, patients with ACPA+/RF+ RA were more likely to initiate abatacept over TNFi as a first-line bDMARD if they had delayed first-line bDMARD initiation, high/moderate disease activity, prior csDMARD use, or were of an older age. There is a need for better understanding of treatment selection and to account for these variables in future studies.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: